Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species

Tina Binderup, Raphaël Duivenvoorden, Francois Fay, Mandy M.T. Van Leent, Joost Malkus, Samantha Baxter, Seigo Ishino, Yiming Zhao, Brenda Sanchez-Gaytan, Abraham J.P. Teunissen, Yohana C.A. Frederico, Jun Tang, Giuseppe Carlucci, Serge Lyashchenko, Claudia Calcagno, Nicolas Karakatsanis, Georgios Soultanidis, Max L. Senders, Philip M. Robson, Venkatesh ManiSarayu Ramachandran, Mark E. Lobatto, Barbara A. Hutten, Juan F. Granada, Thomas Reiner, Filip K. Swirski, Matthias Nahrendorf, Andreas Kjaer, Edward A. Fisher, Zahi A. Fayad, Carlos Pérez-Medina, Willem J.M. Mulder

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Nanomedicine research produces hundreds of studies every year, yet very few formulations have been approved for clinical use. This is due in part to a reliance on murine studies, which have limited value in accurately predicting translational efficacy in larger animal models and humans. Here, we report the scale-up of a nanoimmunotherapy from mouse to large rabbit and porcine atherosclerosis models, with an emphasis on the solutions we implemented to overcome production and evaluation challenges. Specifically, we integrated translational imaging readouts within our workflow to both analyze the nanoimmunotherapeutic's in vivo behavior and assess treatment response in larger animals. We observed our nanoimmunotherapeutic's anti-inflammatory efficacy in mice, as well as rabbits and pigs. Nanoimmunotherapy-mediated reduction of inflammation in the large animal models halted plaque progression, supporting the approach's translatability and potential to acutely treat atherosclerosis.

Original languageEnglish
Article numbereaaw7736
JournalScience Translational Medicine
Issue number506
StatePublished - 21 Aug 2019


Dive into the research topics of 'Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species'. Together they form a unique fingerprint.

Cite this